Nurözler TabakciB,ÜnlüN., 2017.Corticosteroid treatment in diabetic macular edema,Turk J Ophthalmol 47 156 -60
KleinR,KleinBE,MossSE,CruickshanksKJ, 1995.The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema,Ophthalmology 102 7 -16
KleinR,KnudtsonMD,LeeKE,GangnonR,KleinBE, 2009.The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes,Ophthalmology 116 497 -503
DistefanoLN,Garcia-ArumiJ,Martinez-CastilloV,BoixaderaA, 2017.Combination of anti-VEGF and laser photocoagulation for diabetic macular edema: A review,J Ophthalmol 2407037 -
ScottIU,EdwardsAR,BeckRW, 2007.Diabetic retinopathy clinical research network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema,Ophthalmology 114 1860 -7
2010.Diabetic retinopathy clinical research network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema,Ophthalmology 117 1064 -77
2012.Diabetic retinopathy clinical research network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results,Ophthalmology 119 2312 -18
DoDV,NguyenQD,KhwajaAA, 2013.Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment,JAMA Ophthalmol 131 139 -45
ElmanMJ,AyalaA,BresslerNM, 2015.Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results,Ophthalmology 122 375 -81
2011.Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema,Ophthalmology 118 609 -14
CiullaTA,HussainRM,CiullaLM, 2016.Ranibizumab for diabetic macular edema refractory to multiple prior treatments,Retina 36 1292 -7
QiHP,BiS,WeiSQ,CuiH,ZhaoJB, 2012.Intravitreal versus subtenon triamcinolone acetonide injection for diabeticmacular edema: a systematic review and meta-analysis,Curr Eye Res 37 1136 -47
Riazi-EsfahaniM,Riazi-EsfahaniH,AhmadrajiA, 2017.Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial,Int Ophthalmol 27 1045 -6
IslamF,AshrafM,Zafar S, 2016.Retinal thickness and vsual acuity in diabetic macular edema: An optical coherence tomographybased study,J Coll Physicians Surg Pak 26 598 -601
SynekS, .BIntravitreal bevacizumab with or without triamcinolone for refractory diabeticmacular oedema,Coll Antropol 2010 Apr; 34 (Suppl 2 99 -103
AkinciogluD,KüçükevciliogluM,DurukanAH, 2017.Outcomes of intravitreal dexamethasone implant in the treatment of recalcitrant diabetic macular edema,Turk J Ophthalmol 47 274 -8
FurinoC,BosciaF,NiroA, 2017.Combined phacoemulsification and intravitreal dexamethasone implant (Ozurdex®) in diabetic patients with coexisting cataract and diabetic macular edema,J Ophthalmol 4896036 -
CalvoP,FerrerasA,Al AdelF,DangboonW,BrentMH, 2017.Effect of an intravitreal dexamethasone implant on diabetic macular edema after cataract surgery,Retina 10 -
FAMEStudy, 2011.Group: Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema,Ophthalmology 118 626 -35
2012.Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema,Ophthalmology 119 2125 -32
VerittiD,SaraoV,DiplottiL, .Fluocinolone acetonide for the treatment of diabetic macular edema,Expert Opin 18 1507 -16
QureshiNA,AliM,SyedAN, 2010.Mono therapy versus double therapy versus triple therapy in the treatment of diabetic macular edema Al-,Shifa J Ophthalmol 6 74 -80
MehmoodK,MalikBA,KhanMT, 2010.Visual effects of intravitreal triamcinolone acetonide injection in patients with refractory diabetic macular edema,Pak J Ophthalmol 26 193 -6